Page last updated: 2024-12-05

theobromine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Theobromine: 3,7-Dimethylxanthine. The principle alkaloid in Theobroma cacao (the cacao bean) and other plants. A xanthine alkaloid that is used as a bronchodilator and as a vasodilator. It has a weaker diuretic activity than THEOPHYLLINE and is also a less powerful stimulant of smooth muscle. It has practically no stimulant effect on the central nervous system. It was formerly used as a diuretic and in the treatment of angina pectoris and hypertension. (From Martindale, The Extra Pharmacopoeia, 30th ed, pp1318-9) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

theobromine : A dimethylxanthine having the two methyl groups located at positions 3 and 7. A purine alkaloid derived from the cacao plant, it is found in chocolate, as well as in a number of other foods, and is a vasodilator, diuretic and heart stimulator. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
Theobromagenus[no description available]MalvaceaeThe mallow family of the order MALVALES, subclass Dilleniidae, class Magnoliopsida. The common names of hollyhock and mallow are used for several genera of Malvaceae.[MeSH]
Theobroma cacaospecies[no description available]MalvaceaeThe mallow family of the order MALVALES, subclass Dilleniidae, class Magnoliopsida. The common names of hollyhock and mallow are used for several genera of Malvaceae.[MeSH]

Cross-References

ID SourceID
PubMed CID5429
CHEMBL ID1114
CHEBI ID28946
SCHEMBL ID3184
MeSH IDM0021284

Synonyms (198)

Synonym
xantheose
sc-15090 ,
theobromine(20%)
CHEMBL1114 ,
theobrominum
3,7-dimethyl-2,3,6,7-tetrahydro-1h-purine-2,6-dione
nsc-5039
theostene
thesal
1h-purine-2, 3,7-dihydro-3,7-dimethyl-
diurobromine
sc 15090
nsc5039
teobromin
theosalvose
santheose
wln: t56 bn dn fnvmvj b1 f1
3,7-dimethylpurine-2,6-dione
theobromin
CHEBI:28946 ,
3,7-dihydro-3,7-dimethyl-1h-purine-2,6-dione
3,7-dimethyl-3,7-dihydro-1h-purine-2,6-dione
1h-purine-2,6-dione, 3,7-dihydro-3,7-dimethyl-
DIVK1C_000611
KBIO1_000611
SDCCGMLS-0002875.P003
EU-0101187
5-26-13-00553 (beilstein)
1h-purine-2,6-dione,3,7-dihydro-3,7- dimethyl- (9ci)
2,6-dihydroxy-3,7-dimethyl-purine
theobromine, >=98.0%
thesodate
xanthine, 3,7-dimethyl-
nsc 5039
ccris 2350
SPECTRUM_000053
fema no. 3591
theobromine (natural)
brn 0016464
hsdb 7332
einecs 201-494-2
PRESTWICK2_000874
PDSP2_001001
PRESTWICK_1054
NCGC00016023-02
NCGC00016023-01
lopac-t-4500
cas-83-67-0
37T ,
LOPAC0_001187
BSPBIO_001758
NCGC00179030-02
NCGC00179030-01
BPBIO1_001043
PDSP1_001017
PRESTWICK3_000874
BSPBIO_000947
SPECTRUM5_001387
AB00052141
C07480
theobromine
3,7-dimethylxanthine
83-67-0
DB01412
NCGC00024123-05
NCGC00024123-08
NCGC00024123-04
MLS000028407
smr000058357
KBIO2_000433
KBIOGR_000666
KBIOSS_000433
KBIO2_003001
KBIO2_005569
KBIO3_001258
PRESTWICK0_000874
SPECTRUM2_000985
SPBIO_002868
PRESTWICK1_000874
SPBIO_001049
SPECTRUM3_000279
NINDS_000611
SPECTRUM4_000403
SPECTRUM1500649
IDI1_000611
NCGC00024123-03
NCGC00024123-07
NCGC00024123-06
NCGC00016023-03
NCGC00016023-06
AC-11381
T 4500
HMS2092G04
CEC63CCA-3B4B-4F4F-92C1-1789DF3C880A
NCGC00016023-14
yapqbxqyljrxsa-uhfffaoysa-
inchi=1/c7h8n4o2/c1-10-3-8-5-4(10)6(12)9-7(13)11(5)2/h3h,1-2h3,(h,9,12,13)
HMS501O13
FT-0660435
T0178
HMS1570P09
HMS1921O13
bdbm50014260
NCGC00016023-11
AKOS000121558
HMS3263N15
HMS2097P09
3,7-dimethyl-1,3,7-trihydropurine-2,6-dione
tox21_300016
NCGC00253943-01
pharmakon1600-01500649
nsc757407
nsc-757407
dtxcid506132
dtxsid9026132 ,
tox21_110284
CCG-40078
NCGC00016023-10
NCGC00016023-15
NCGC00016023-07
NCGC00016023-13
NCGC00016023-12
NCGC00016023-05
NCGC00016023-04
NCGC00016023-08
NCGC00016023-09
7-dimethylxanthine
2,6-dihydroxy-3,7-dimethylpurine
FT-0675138
unii-obd445wz5p
5-26-13-00553 (beilstein handbook reference)
obd445wz5p ,
theobromine [inn:ban:nf]
NCGC00016023-17
519-41-5
LP01187
pentoxifylline impurity a [ep impurity]
theobromine [mart.]
caffeine monohydrate impurity d [ep impurity]
theobromine [hsdb]
theobromine [iarc]
theobromine [mi]
theobromine [fhfi]
theobromine [who-dd]
theobrominum [hpus]
theobromine [ep impurity]
theobromine [vandf]
theobromine [inci]
S2368
3,7-dimethylxanthin
3,7-dimethyl-1h-purine-2,6(3h,7h)-dione
SCHEMBL3184
tox21_110284_1
NCGC00016023-18
NCGC00261872-01
tox21_501187
3,7-dimethyl-3,7-dihydro-1h-purine-2,6-dione #
BBL034679
STL419465
AC-34381
Q-100848
HY-N0138
CS-7972
theobromine, pharmaceutical secondary standard; certified reference material
AB00052141_12
mfcd00022830
theobromine, >=98.0% (hplc)
3, 7-dimethylxanthine
SR-01000000069-2
sr-01000000069
theobromine, analytical standard
theobromine, european pharmacopoeia (ep) reference standard
theobromine 0.1 mg/ml in methanol
SR-01000000069-4
SR-01000000069-9
SR-01000000069-10
SR-01000000069-7
SR-01000000069-8
SBI-0051154.P003
HMS3714P09
Z56347209
theobromine;
3,7-dimethylxanthine; 3,7-dimethylpurine-2,6-dione
3,7-dimethyl-1h-purine-2,6-dione
SY048379
theobromine (3,7-dimethylxanthine)
AS-13904
Q206844
BRD-K34888156-001-08-8
EN300-16609
SDCCGSBI-0051154.P004
NCGC00016023-26
D71206
theobromine (ep impurity)
theobromine (mart.)
theobromine (iarc)
pentoxifylline impurity a (ep impurity)
caffeine ep impurity d

Research Excerpts

Overview

Theobromine is a caffeine metabolite most abundant in dark chocolate, of which consumption is linked with a lower risk of cognitive decline. It is a xanthine derivative, structurally related to the nucleobases, and also present in many living beings.

ExcerptReferenceRelevance
"Theobromine is a common ingredient of many natural foods consumed by a large population worldwide."( Neuroprotective Effects of Theobromine in permanent bilateral common carotid artery occlusion rat model of cerebral hypoperfusion.
Bhat, JA; Kumar, M, 2022
)
1.74
"Theobromine is a caffeine metabolite most abundant in dark chocolate, of which consumption is linked with a lower risk of cognitive decline. "( Thebromine Targets Adenosine Receptors to Control Hippocampal Neuronal Function and Damage.
Alçada-Morais, S; Cunha, RA; Lopes, JP; Valada, P, 2022
)
2.16
"Theobromine is an abundant methylxanthine in cocoa/chocolate. "( One-way or two-way sweet link between theobromine and depression?
Franco, R; Martínez-Pinilla, E, 2023
)
2.62
"Theobromine is a xanthine derivative, structurally related to the nucleobases, and also present in many living beings."( Exploration of the theobromine-water dimer: comparison with DNA microhydration.
Calabrese, C; Camiruaga, A; D'mello, VC; Fernández, JA; Usabiaga, I; Veloso, A; Wategaonkar, S, 2020
)
1.61
"Theobromine is a natural methylxanthine present in dark chocolate particularly abundant in cocoa bean shell."( Efficacy of theobromine in preventing intestinal CaCo-2 cell damage induced by oxysterols.
Biasi, F; Iaia, N; Poli, G; Rossin, D; Sottero, B; Venezia, I, 2020
)
1.66
"Theobromine is a caffeine derivative and the primary methylxanthine in Theobroma cacao. "( Chronic administration of theobromine inhibits mTOR signal in rats.
Katakura, M; Matsuzaki, K; Shido, O; Sugimoto, N; Sumiyoshi, E; Yachie, A, 2019
)
2.26
"Theobromine, which is a caffeine derivative, is the primary methylxanthine produced by Theobroma cacao. "( Theobromine up-regulates cerebral brain-derived neurotrophic factor and facilitates motor learning in mice.
Katakura, M; Matsuzaki, K; Ohno-Shosaku, T; Shido, O; Sugimoto, N; Tanigami, H; Yachie, A; Yoneda, M, 2017
)
3.34
"Theobromine is a good model compound for assessing the activity of these enzymes in man as it has low pharmacological activity and low protein binding, its total and partial metabolic clearances correlate closely with those of theophylline, and close to 100% of the dose can be recovered as known metabolites."( Comparison of theophylline and theobromine metabolism in man.
Billing, B; Birkett, DJ; Dahlqvist, R; Lelo, A; Miners, JO,
)
1.14

Effects

Theobromine (TB) has been reported to promote tooth remineralization, strengthen tooth substance, and relieve dentin hypersensitivity. TB has some pharmacological effects, although these activities are considerably weaker than those of theophylline and/or caffeine.

ExcerptReferenceRelevance
"Theobromine has shown health benefits in several studies, attributed to regulation of calcium homeostasis, phosphodiesterase, neurotransmission, and neurotrophins."( Neuroprotective Effects of Theobromine in permanent bilateral common carotid artery occlusion rat model of cerebral hypoperfusion.
Bhat, JA; Kumar, M, 2022
)
1.74
"Theobromine (TB) has been reported to promote tooth remineralization, strengthen tooth substance, and relieve dentin hypersensitivity. "( Bacterial adhesion and antibacterial property of coating materials containing theobromine and S-PRG filler.
Burrow, MF; Hotta, M; Ichimura, Y; Ikeda, M; Kitada, N; Kusakabe, S; Nikaido, T; Shimizu, S; Takagaki, T; Toyama, M; Yamamoto, K, 2023
)
2.58
"Theobromine has also been shown to improve lipoprotein levels in trials, although these findings need verification at habitual intake levels."( Flavan-3-ols, theobromine, and the effects of cocoa and chocolate on cardiometabolic risk factors.
Berends, LM; Cassidy, A; van der Velpen, V, 2015
)
1.5
"Theobromine has to exceed a threshold level of 2 microg/mL, hence a robust and reliable quantitation is required."( Electrospray ionization mass spectrometric characterization and quantitation of xanthine derivatives using isotopically labelled analogues: an application for equine doping control analysis.
Krug, O; Opfermann, G; Schänzer, W; Thevis, M, 2004
)
1.04
"Theobromine tablets have been prepared by wet granulation using gelatin solutions of various concentrations. "( [Effect of gelatin solution on parameters of tablets containing well-compressible active principles].
Gyurkó, E; Miseta, M; Pintyéné, HK; Selmeczi, B; Szabóné, RP, 1989
)
1.72
"Theobromine has some pharmacological effects, although these activities are considerably weaker than those of theophylline and/or caffeine, described in parts 1 and 2 of this series (Stavric, Fd Chem."( Methylxanthines: toxicity to humans. 3. Theobromine, paraxanthine and the combined effects of methylxanthines.
Stavric, B, 1988
)
1.26

Actions

The theobromine in cocoa plays an immunoregulatory role that is responsible for cocoa's influence on both systemic and intestinal antibody concentrations. As theobrome and fat increase fasting apoA-I concentrations, and the intestine is involved in apoC-I production, the acute effects of both were studied.

ExcerptReferenceRelevance
"As theobromine and fat increase fasting apoA-I concentrations, and the intestine is involved in apoA-I production, the acute effects of both were studied on duodenal gene transcription to better understand underlying mechanisms."( The acute effects on duodenal gene expression in healthy men following consumption of a low-fat meal enriched with theobromine or fat.
Boekschoten, MV; de Ridder, RJJ; Mensink, RP; Plat, J; Smolders, L, 2018
)
1.2
"The theobromine in cocoa plays an immunoregulatory role that is responsible for cocoa's influence on both systemic and intestinal antibody concentrations and also for modifying lymphoid tissue lymphocyte composition in young healthy Lewis rats. "( Theobromine Is Responsible for the Effects of Cocoa on the Antibody Immune Status of Rats.
Camps-Bossacoma, M; Castell, M; Franch, À; Pérez-Cano, FJ, 2018
)
2.48
"Theobromine did not produce changes in group ratings but changed ratings in some subjects."( Discriminative stimulus and subjective effects of theobromine and caffeine in humans.
Evans, SM; Griffiths, RR; Kaminski, BJ; Mumford, GK; Preston, KL; Sannerud, CA; Silverman, K, 1994
)
1.26

Treatment

Treatment with theobromine significantly attenuated neurological deficits and improved sensorimotor functions and memory in rats with CH. Theobromin-enriched cocoa resulted in a mean±SE of 3.2±1.1 mm Hg higher 24-hour ambulatory systolic blood pressure compared with placebo (P<0.01)

ExcerptReferenceRelevance
"L-theobromine was treated as a log transform and dichotomous form (the highest quantile vs. "( Association between Dietary Theobromine and Cognitive Function in a Representative American Population: A Cross-Sectional Study.
Chen, N; Gao, L; Ge, W; Guo, J; He, L; Peng, C, 2022
)
1.74
"Theobromine treatment increased AMPK phosphorylation and knockdown of AMPKα1/α2 prevented the ability of theobromine to inhibit PPARγ expression in the differentiating 3T3-L1 cells."( Theobromine inhibits differentiation of 3T3-L1 cells during the early stage of adipogenesis via AMPK and MAPK signaling pathways.
Jang, YJ; Kang, SC; Koo, HJ; Pyo, S; Rhee, DK; Sohn, EH, 2015
)
2.58
"Treatment with theobromine significantly attenuated neurological deficits and improved sensorimotor functions and memory in rats with CH."( Neuroprotective Effects of Theobromine in permanent bilateral common carotid artery occlusion rat model of cerebral hypoperfusion.
Bhat, JA; Kumar, M, 2022
)
1.36
"Treatment with theobromine-enriched cocoa resulted in a mean±SE of 3.2±1.1 mm Hg higher 24-hour ambulatory systolic blood pressure compared with placebo (P<0.01)."( Effects on peripheral and central blood pressure of cocoa with natural or high-dose theobromine: a randomized, double-blind crossover trial.
Draijer, R; van den Bogaard, B; van den Born, BJ; van den Meiracker, AH; van Montfrans, GA; Westerhof, BE, 2010
)
0.92
"Treatment with theobromine produced a significant increase in the contents of hydroxylysine, hydroxyproline, and proline in both anterior and posterior sclera, while 7-methylxanthine increased the contents of hydroxyproline and proline selectively in posterior sclera. "( Biochemical and ultrastructural changes in rabbit sclera after treatment with 7-methylxanthine, theobromine, acetazolamide, or L-ornithine.
Kobayashi, T; Olsen, EB; Ribel-Madsen, SM; Trier, K, 1999
)
0.87

Toxicity

Theobromine, 1-benzyl-theobrome-thioacetic acid (BTTA) and the other new theobromaine derivatives were devoid of toxicity. The influence of theobrome or pentoxifylline with ADR on the lipid peroxide level and on DNA biosynthesis was examined.

ExcerptReferenceRelevance
" In summary, pentoxifylline improved function and symptoms in 13 of 22 geriatric patients with intermittent claudication; the drug was safe and well tolerated at the usual dosage in this geriatric patient population."( Efficacy and safety of pentoxifylline in geriatric patients with intermittent claudication.
Cobert, BL; Cohn, JB; Crowder, JE; Hryniewicki, SW; Morgan, DL; Piccirillo, RT; Savitsky, JP; Slywka, J; Wilcox, CS, 1989
)
0.28
" Critical review of toxic manifestations due to exposure to relatively large doses of caffeine and theophylline indicates that such combined exposure may potentiate the toxic effects of either drug."( Methylxanthines: toxicity to humans. 3. Theobromine, paraxanthine and the combined effects of methylxanthines.
Stavric, B, 1988
)
0.54
"Jimson weed seed meal, which contains alkaloids toxic to animals, and cocoa shell meal, which contains theobromine, also toxic to animals, were used in two experiments with broilers to determine relative toxicity."( Toxicity of jimson weed seed and cocoa shell meal to broilers.
Day, EJ; Dilworth, BC, 1984
)
0.48
" Results indicated that the lowest concentration of guarana tested was not toxic and that the IC50 values calculated with the NR, KB, and MTT assays were lower than the highest concentration tested (40 mg/ml)."( Evaluation of the toxicity of guarana with in vitro bioassays.
Diaz, MM; Lopez, A; Muñoz-Mingarro, D; Pozuelo, JM; Santa Maria, A, 1998
)
0.3
" The influence of the combination of theobromine or pentoxifylline with ADR on the lipid peroxide level (indicating the ADR-induced side effect) and on DNA biosynthesis (indicating the side effect and antitumor activity) were examined."( [Effects of methylxanthine derivatives on antitumor activity and toxic side effect of adriamycin induced by inhibition of DNA biosynthesis].
Hirota, S; Iwazaki, A; Sadzuka, Y, 1998
)
0.57
" Histopathological examination of reproductive organs revealed toxic findings in the testis at 500 mg/kg after 2 weeks of dosing at both ages, and at 250 and 500 mg/kg after 4 weeks of dosing."( Collaborative work to evaluate toxicity on male reproductive organs by repeated dose studies in rats 22). Effects of 2- and 4-week administration of theobromine on the testis.
Fujioka, M; Funabashi, H; Kohchi, M; Matsuoka, N; Tateishi, Y, 2000
)
0.51
" On isolated rat microsomes only 7d showed toxic effect while theobromine, 1-benzyl-theobromine-thioacetic acid (BTTA) and the other new theobromine derivatives were devoid of toxicity."( Determination of the Antiproliferative Activity of New Theobromine Derivatives and Evaluation of Their In Vitro Hepatotoxic Effects.
Georgieva, M; Kondeva-Burdina, M; Mitkov, J; Momekov, G; Tzankova, V; Zlatkov, A, 2016
)
0.92
" Thus, the repeated dose study of 7-MX for 180 days may augment the possibility of using 7-MX clinically for the safe and effective treatment of myopia."( Sub-chronic and chronic toxicity evaluation of 7-methylxanthine: a new molecule for the treatment of myopia.
Jain, SK; Kaur, I; Paul, S; Sahajpal, NS; Singh, H, 2022
)
0.72

Pharmacokinetics

ExcerptReferenceRelevance
" The pharmacokinetic profile of caffeine in the suckling pup following iv bolus administration (5 mg/kg) was more prolonged compared with adult rabbits."( Pharmacokinetics of caffeine and its demethylated metabolites in lactating adult rabbits and neonatal offspring. Predictions of breast milk to serum concentration ratios.
Burgio, D; McNamara, PJ; Yoo, SD,
)
0.13
" After a 100 mg intravenous infusion, pentoxifylline elimination half-life was prolonged in cirrhotic patients (2."( Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patients.
Cheymol, G; Grange, JD; Jaillon, P; Lecocq, B; LeCoz, F; Midavaine, M; Poirier, JM; Poupon, R; Rames, A, 1990
)
0.28
" Pharmacokinetic characteristics of the drugs were similar except that HWA-285 produced lower concentrations in serum and A81-3138 showed a dose-dependent kinetics (longer half-life at a higher dose)."( Efficacy, toxicity, and pharmacokinetics of pentoxifylline and its analogs in experimental Staphylococcus aureus infections.
Breaux, S; Krause, PJ; Maderazo, EG; Woronick, CL, 1990
)
0.28
"001) and no significant differences were observed in the pharmacokinetic data derived from the respective concentration-time curves."( The pharmacokinetics of caffeine and its dimethylxanthine metabolites in patients with chronic liver disease.
Chakraborty, J; Marks, V; Morgan, MY; Scott, NR; Stambuk, D, 1989
)
0.28
" Although the mechanisms of action of the two drugs may overlap, the pharmacodynamic activity of warfarin was not significantly altered when pentoxifylline was coadministered."( Lack of pharmacodynamic interaction between pentoxifylline and warfarin in the rat.
Keane, WF; Luke, DR; Matzke, GR; O'Donnell, MP, 1986
)
0.27
" The mean peak serum concentrations of both drugs, the time at which peak serum concentrations occurred, and elimination half-life values were similar for theobromine and theophylline."( The bronchodilator effect and pharmacokinetics of theobromine in young patients with asthma.
Becker, AB; Gillespie, CA; Simons, FE; Simons, KJ, 1985
)
0.72
" The serum concentration-time curves for each animal were analyzed separately to estimate model-independent pharmacokinetic variables."( Comparative pharmacokinetics of caffeine and three metabolites in clinically normal horses and donkeys.
Matthews, NS; Mealey, KL; Peck, K; Taylor, TS, 1997
)
0.3
"Mean pharmacokinetic values for caffeine, theophylline, and paraxanthine did not differ significantly in horses, compared with donkeys."( Comparative pharmacokinetics of caffeine and three metabolites in clinically normal horses and donkeys.
Matthews, NS; Mealey, KL; Peck, K; Taylor, TS, 1997
)
0.3
" The elimination half-life (t(1/2)) was 31."( The pharmacokinetics, metabolism and urinary detection time of caffeine in camels.
Abdel Hadi, AA; Alkatheeri, NA; Almuhrami, AM; Barezaig, IM; Boni, NS; Elghazali, M; Wasfi, IA, 2000
)
0.31
" The validity of the human kinetic subfactor has been analysed in relation to CYP1A2 metabolism using published in vivo pharmacokinetic parameters selected to reflect chronic exposure (metabolic and total clearances and area under the plasma concentration-time curve: CLm, CL and AUC) and acute exposure (the peak plasma concentration, C(max))."( Uncertainty factors for chemical risk assessment. human variability in the pharmacokinetics of CYP1A2 probe substrates.
Dorne, JL; Renwick, AG; Walton, K, 2001
)
0.31
"The stimulant effect of caffeine, as an additive in diacetylmorphine preparations for study purposes, may interfere with the pharmacodynamic effects of diacetylmorphine."( Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine.
Beijnen, JH; de Jonge, ME; den Hoed, R; Hendriks, VM; Huitema, AD; Sparidans, RW; van den Brink, W; van Ree, JM; Zandvliet, AS, 2005
)
0.57
" Therefore, we characterized the potencies, selectivities, and pharmacokinetic profiles of six prototypical A2A -antagonists."( Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists.
Belardinelli, L; Chu, N; Diamond, I; Kalla, R; Leung, K; Shryock, JC; Soelaiman, S; Soohoo, D; Yang, M; Yao, L; Zablocki, J, 2007
)
0.34
"This study sought to assess the pharmacokinetic (PK) changes of caffeine and its CYP1A2 metabolites across the 3 trimesters of pregnancy."( Pregnancy-induced changes in the pharmacokinetics of caffeine and its metabolites.
Campbell, SC; Clark, EA; Schoen, K; Sherwin, CM; Spigarelli, MG; Stockmann, C; Tak, C; Varner, MW; Yu, T, 2016
)
0.43

Compound-Compound Interactions

ExcerptReferenceRelevance
" In the current study, stepwise injection analysis (SWIA) was successfully combined with single-drop liquid microextraction (SDLME) and solvent exchange procedure."( Stepwise injection potentiometric determination of caffeine in saliva using single-drop microextraction combined with solvent exchange.
Bulatov, A; Kirsanov, D; Medinskaia, K; Nikolaeva, L; Timofeeva, I, 2016
)
0.43
" The metabolic profile of guarana from the two largest producing regions was investigated using UPLC-MS combined with multivariate statistical analysis."( Chemical profiling of guarana seeds (Paullinia cupana) from different geographical origins using UPLC-QTOF-MS combined with chemometrics.
Canuto, KM; Coutinho, JP; da Silva, GS; de Brito, ES; de Jesus, RM; Nascimento, MM; Ribeiro, PRV; Zocolo, GJ, 2017
)
0.46

Bioavailability

ExcerptReferenceRelevance
" After oral administration of a 400 mg sustained-released tablet, absolute bioavailability of pentoxifylline increased in cirrhotic patients (0."( Pharmacokinetics of intravenous and oral pentoxifylline in healthy volunteers and in cirrhotic patients.
Cheymol, G; Grange, JD; Jaillon, P; Lecocq, B; LeCoz, F; Midavaine, M; Poirier, JM; Poupon, R; Rames, A, 1990
)
0.28
"The pharmacokinetics and relative bioavailability of pentoxifylline, from a new sustained-release formulation (Oxopurin) and from a standard sustained-release formulation (Trental-400), were compared in 8 healthy adult male volunteers."( Comparative pharmacokinetic analysis of novel sustained-release dosage forms of pentoxifylline in healthy subjects.
Ben-David, J; Hussein, Z; Raz, I; Samara, E, 1988
)
0.27
" Since serum TBR concentrations and overall toxicity were lower in Ch + TBR-treated animals than in S + TBR treated animals, yet TBR bioavailability was similar, this effect was attributed to the inducing potential of the Ch diet on TBR metabolism and clearance."( Diet-induced alterations in theobromine disposition and toxicity in the rat.
Shively, CA; Tarka, SM; White, DM, 1986
)
0.57
" Urinary excretion of two acid metabolites after oral and intravenous dosing indicated almost complete absorption of drug-related substances from both of the oral formulations, although bioavailability averaged 20% to 30%."( Kinetics of intravenous and oral pentoxifylline in healthy subjects.
Beermann, B; Chamberlain, J; Ings, R; Månsby, J; McDonald, A, 1985
)
0.27
" Relative bioavailability of theobromine in chocolate was 80% that of theobromine in solution."( High levels of methylxanthines in chocolate do not alter theobromine disposition.
Arnaud, MJ; Dvorchik, BH; Passananti, GT; Shively, CA; Tarka, SM; Vesell, ES, 1985
)
0.81
" Like other methylxanthines, pentoxifylline is well absorbed in the gastrointestinal tract, almost completely metabolized in the body and excreted in the urine."( Pentoxifylline: a new drug for the treatment of intermittent claudication. Mechanism of action, pharmacokinetics, clinical efficacy and adverse effects.
Aviado, DM; Porter, JM,
)
0.13
" No significant difference was found in the pharmacokinetic profile of the drug after acute or chronic treatment at different doses except for a reduction in the absorption rate constant as the dose increased."( Kinetics and metabolism of theobromine in male rats.
Arnaud, MJ; Bonati, M; Borzelleca, JF; Galletti, F; Garattini, S; Latini, R; Riva, E; Sadurska, B; Tarka, SM, 1984
)
0.56
" Irrespective of sex, there was a reduction in the absorption rate constant as the dose increased, coupled with a linear dose-related increase in AUC values."( Kinetics and metabolism of theobromine in male and female non-pregnant and pregnant rabbits.
Arnaud, MJ; Bonati, M; Bortolotti, A; Borzelleca, JF; Garattini, S; Gaspari, F; Jiritano, L; Latini, R; Tarka, SM; Traina, GL, 1984
)
0.56
" An analysis of the published literature showed that the absorption, bioavailability and route of excretion were generally similar between humans and the test species, for each probe substrate."( Uncertainty factors for chemical risk assessment: interspecies differences in the in vivo pharmacokinetics and metabolism of human CYP1A2 substrates.
Dorne, JL; Renwick, AG; Walton, K, 2001
)
0.31
" The bioavailability was approximately 60%."( Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine.
Beijnen, JH; de Jonge, ME; den Hoed, R; Hendriks, VM; Huitema, AD; Sparidans, RW; van den Brink, W; van Ree, JM; Zandvliet, AS, 2005
)
0.57
" The bioavailability of this polyphenol-rich cocoa powder developed at pilot scale was previously demonstrated in humans."( Antihypertensive effect of a polyphenol-rich cocoa powder industrially processed to preserve the original flavonoids of the cocoa beans.
Aleixandre, A; Cienfuegos-Jovellanos, E; Miguel, M; Moulay, L; Muguerza, B; Quiñones, Mdel M, 2009
)
0.35
" The cocrystals outperformed QUE dihydrate with increases in bioavailability up to nearly 10-fold."( Cocrystals of quercetin with improved solubility and oral bioavailability.
Kavuru, P; Shytle, RD; Smith, AJ; Wojtas, L; Zaworotko, MJ, 2011
)
0.37
" Oligomeric procyanidins are poorly absorbed in the small intestine, but catabolites are very efficiently absorbed after microbial biotransformation in the colon."( Cocoa and human health.
Ellam, S; Williamson, G, 2013
)
0.39
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Hence, using nanotechnology is a viable alternative to primarily improve the physicochemical characteristics and bioavailability of guarana."( Protective effect of guarana-loaded liposomes on hemolytic activity.
da Cruz, IBM; Dalcin, AJF; Gomes, P; Mitjans, M; Ourique, AF; Ribeiro, EE; Roggia, I; Vinardell, MP, 2020
)
0.56
" Recent studies showed that flavan-3-ols could interact with methylxanthines, evidenced by an increase in flavan-3-ol bioavailability with a concomitant increase in flavan-3-ol intake-mediated vascular effects."( Flavan-3-ol-methylxanthine interactions: Modulation of flavan-3-ol bioavailability in volunteers with a functional colon and an ileostomy.
Borges, G; Crozier, A; Dobani, S; Durkan, R; Ensunsa, JL; Fong, RY; Gill, CIR; Kane, E; Kimball, J; Lawther, R; Medici, V; O'Connor, G; Ottaviani, JI; Pourshahidi, LK; Schroeter, H; Ward, K, 2023
)
0.91

Dosage Studied

Theobromine metabolism and clearance were investigated at steady-state under chronic oral dosing conditions in eight healthy volunteers, four of whom were cigarette smokers. Sprague-Dawley rats were weighed and dosed daily for 31 days with vehicle, 250 mg/kg theobrome, 2.5% caffeine, and theophylline. Dose-response relationship analysis indicated nonlinear correlations between the likelihood of low cognitive performance and die-tary theobroma.

ExcerptRelevanceReference
" These findings suggest that CA pharmacokinetic parameters can be estimated using a simplified three-point blood sampling procedure following a single oral load and that the serum PX/CA or (PX + TB + TP)/CA ratio in a single blood sample taken 2 or 4 h after dosing provides a useful indicator for the assessment of hepatic drug-oxidizing capacity, N-demethylation, in decompensated liver cirrhosis."( A simple useful method for the determination of hepatic function in patients with liver cirrhosis using caffeine and its three major dimethylmetabolites.
Fukao, K; Ishikawa, A; Iwasaki, Y; Misawa, S; Osada, A; Tanaka, E; Tsuji, K; Yamamoto, Y, 1992
)
0.28
" However, the effects of the four agents on the clonal survival of irradiated cells failed to correlate with the extent of override, both in terms of the relative effects of the four agents and the dose-response relationships; at a concentration of 1 mM only caffeine was found to potentiate cell killing as well as causing block override, whilst at higher concentrations all the agents had a significant effect on survival but little or no further influence on the degree of block override."( Override of the radiation-induced mitotic block in human tumour cells by methylxanthines and its relationship to the potentiation of cytotoxicity.
Musk, SR; Steel, GG, 1990
)
0.28
" Statistically significant dose-response increases of red cell filterability were found 4 and 6 hours after oral medication with the dosages of 200 to 1200 mg pentoxifylline."( Dose-response effects of pentoxifylline on erythrocyte filterability: clinical and animal model studies.
Ambrus, JL; Anain, JM; Anain, PM; Anain, SM; Brobst, JA; Cobert, BL; Mitchell, P; Savitsky, JP; Stadler, S, 1990
)
0.28
"Some recent epidemiologic studies have reported a nonlinear dose-response in the relationship between coffee consumption and health risks, such that the risks increase disproportionately to the increase in dose."( Dose-dependency of caffeine metabolism with repeated dosing.
Benowitz, NL; Brown, CR; Denaro, CP; Jacob, P; Wilson, M, 1990
)
0.28
" In summary, pentoxifylline improved function and symptoms in 13 of 22 geriatric patients with intermittent claudication; the drug was safe and well tolerated at the usual dosage in this geriatric patient population."( Efficacy and safety of pentoxifylline in geriatric patients with intermittent claudication.
Cobert, BL; Cohn, JB; Crowder, JE; Hryniewicki, SW; Morgan, DL; Piccirillo, RT; Savitsky, JP; Slywka, J; Wilcox, CS, 1989
)
0.28
" Urine samples were collected for 24 hours after dosing and analyzed for pentoxifylline and its metabolites using high-performance liquid chromatography coupled with an ultraviolet detector."( Urinary excretion of pentoxifylline and its metabolites by standardbred mares.
Chen, FC; Kwong, EC; Young, LM, 1989
)
0.28
" The dosed 14C material (96."( Metabolism and pharmacokinetics of 14C-pentoxifylline in healthy volunteers.
Bryce, TA; Chamberlain, J; Hillbeck, D; Macdonald, CM, 1989
)
0.28
"Theobromine metabolism and clearance were investigated at steady-state under chronic oral dosing conditions in eight healthy volunteers, four of whom were cigarette smokers."( Influence of cimetidine, sulfinpyrazone, and cigarette smoking on theobromine metabolism in man.
Attwood, J; Birkett, DJ; Miners, JO; Wing, LM,
)
1.81
" Pentoxifylline and metabolite plasma concentrations over one dosing interval were measured on day 7 of each phase."( Alteration of pentoxifylline pharmacokinetics by cimetidine.
Hageman, JH; Mauro, LS; Mauro, VF, 1988
)
0.27
" In most studies, the recommended dosage of Trental was 3 X 400 mg pentoxifylline in sustained release tablets."( On the assessment of the efficacy of pentoxifylline (Trental).
Müller, R; Rössner, M, 1987
)
0.27
" In patients with cerebrovascular disorders, open studies with pentoxifylline, usually at a dosage of 600 to 1200 mg/day (300 to 600 mg/day in Japan), have shown marked overall clinical improvements in about 85% of patients."( Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy.
Clissold, SP; Ward, A, 1987
)
0.27
" Consequently, when a dialysis patient required this drug, we started at a low dose and gradually increased the dosage while monitoring the patient for signs or symptoms of toxicity and following plasma concentrations of parent drug and its metabolites."( Pentoxifylline in end-stage renal disease.
Kroboth, PD; Silver, MR, 1987
)
0.27
" Patients received a daily dosage of 2200 mg, given as 800 mg orally and 300 mg by intravenous infusion in saline twice daily, for a mean period of 15."( Results of clinical, laboratory and haemorheological investigations of the use of pentoxifylline in high doses.
Antignani, PL; Bartolo, M; Pacino, G; Saliceti, F; Todini, AR, 1987
)
0.27
" Patients received pentoxifylline on a combined intravenous/oral dosage regimen for 3 weeks and then were maintained on 800 mg orally for a further 2 weeks."( Beneficial results of pentoxifylline ('Trental') therapy in arteriosclerosis obliterans: possible mechanism of action.
Bieroń, K; Dembińska-Kieć, A; Grodzińska, L; Gryglewski, RJ; Kostka-Trabkowa, E, 1985
)
0.27
" Adverse reactions are mainly of the gastrointestinal type and are minimized by the use of a controlled-release dosage form."( Pentoxifylline: a new agent for intermittent claudication.
Baker, DE; Campbell, RK, 1985
)
0.27
" However, in the rare situation in which repeated significant bleeding occurs despite careful adjustment of the dosage of warfarin, PST may be an acceptable alternate method of thromboembolism prophylaxis."( Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective randomized clinical trial.
Boey, J; Chan, TK; Cheung, KL; Chow, J; Lee, PK; Mok, CK; Ng, RP; Tse, TF; Wang, R, 1985
)
0.27
" The present pharmacokinetic results further support the use of a controlled-release dosage form of pentoxifylline for therapy."( Pharmacokinetics of orally administered pentoxifylline in humans.
Bauza, MT; Doluisio, JT; Ho, I; Lassman, HB; Puri, SK; Smith, RV; Waller, ES, 1986
)
0.27
" Cumulation of pentoxifylline in plasma after repeated dosing was minimal."( Kinetics of intravenous and oral pentoxifylline in healthy subjects.
Beermann, B; Chamberlain, J; Ings, R; Månsby, J; McDonald, A, 1985
)
0.27
" Urine samples were collected for 24 h after dosing and analysed for caffeine and eleven of its metabolites by high-performance liquid chromatography."( Comparison of the urinary metabolite profile of caffeine in young and elderly males.
Blanchard, J; Jonkman, JH; Sawers, SJ; Tang-Liu, DD, 1985
)
0.27
"A long-term trial with oral pentoxifylline ("Trental" 400) in a dosage of 1200 mg per day was carried out in 70 diabetic patients with and without vascular afflictions."( Diabetic retinal vascular complications and erythrocyte filtrability; results of a 2-year follow-up study with pentoxifylline.
Ferrari, E; Solerte, SB, 1985
)
0.27
" No difference was found between baseline and pathological conditions, or between dosing and sampling at different sites."( Pharmacokinetics of theobromine in male rats in different traumatic conditions.
Bonati, M; Bortolotti, A, 1985
)
0.59
"The kinetics and metabolism of theobromine (3,7- DMX ) were investigated in male rabbits after a single oral dose and 14 days oral dosing at 1, 5, 10, 50 and 100 mg/kg/day."( Kinetics and metabolism of theobromine in male and female non-pregnant and pregnant rabbits.
Arnaud, MJ; Bonati, M; Bortolotti, A; Borzelleca, JF; Garattini, S; Gaspari, F; Jiritano, L; Latini, R; Tarka, SM; Traina, GL, 1984
)
0.85
" Before establishing dosage levels for a chronic toxicity study, the pharmacokinetics of the dose must be determined in the species that will be used in long-term studies."( The toxicology of cocoa and methylxanthines: a review of the literature.
Tarka, SM, 1982
)
0.26
" The kinetic parameters of P rats were strikingly similar to NP rats at all TBR dosage levels employed."( Theobromine metabolism and pharmacokinetics in pregnant and nonpregnant Sprague-Dawley rats.
Shively, CA; Tarka, SM, 1983
)
1.71
" Roasted cocoa freed from fat produced distinctly higher SCE values with a linear dose-response relationship, whereas cocoa butter had no influence on SCE levels."( Genotoxicity of cocoa examined by microbial and mammalian systems.
Münzner, R; Renner, HW, 1982
)
0.26
" The treatment usually comprised two months with a daily dosage of 800 mg up to 1200 mg (2 to 3 coated tablets Trental forte per day)."( [Trental forte in leg ulcer therapy. Result of a field study].
Schmidt-Modrow, G; Weitgasser, H, 1982
)
0.26
" Of the three loading doses tested, only the highest showed any side effects, these being transient and occurring within a 5 to 10 min period after dosing and appeared to correlate with the high initial plasma levels of the drug."( The pharmacokinetics of oxpentifylline in man when administered by constant intravenous infusion.
Bryce, TA; Burrows, JL; Ings, RM; Nüdemberg, F, 1982
)
0.26
" Dose-response studies showed that the maximal excretion of urinary PGE and water was obtained by administration of theophylline (50 mg/kg), where the increase in PGE was about 20 times that of the control."( Effects of methylxanthines on urinary prostaglandin E excretion in rats.
Aizawa, Y; Kogo, H; Takeuchi, K, 1981
)
0.26
" pretreatment with DMPX, an adenosine receptor antagonist exhibiting selectivity for striatal A2 receptors, at a dosage which alone had no significant effect on locomotor activity."( Role of adenosine A2a receptors in the nucleus accumbens.
Barraco, RA; Martens, KA; Normile, HJ; Parizon, M, 1994
)
0.29
" Successively higher concentrations of DMPX shifted the dose-response curve of NECA to the right in a nearly parallel fashion."( Adenosine stimulates human sperm motility via A2 receptors.
Chen, SS; Chiang, PH; Linden, J; Shen, MR; Wu, SN, 1993
)
0.29
" It is concluded that oxypentifylline used in the present dosage reduces the intensity of acute GVHD following allogeneic bone marrow transplantation and is also well tolerated by the patient."( Does oxypentifylline reduce the intensity of acute graft-versus-host disease following allogeneic bone marrow transplantation?
Ghosh, K; Hutchinson, RM, 1996
)
0.29
"Groups of pigmented rabbits, six in each group, were dosed during 10 weeks with one of the substances under investigation, and one untreated group was the control."( Biochemical and ultrastructural changes in rabbit sclera after treatment with 7-methylxanthine, theobromine, acetazolamide, or L-ornithine.
Kobayashi, T; Olsen, EB; Ribel-Madsen, SM; Trier, K, 1999
)
0.52
" Caffeine, theophylline, and paraxanthine shifted the dose-response curve for adenosine at the A1, A2A, and A2B receptors."( Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells.
Fredholm, BB; Irenius, E; Kull, B; Schulte, G, 2001
)
0.31
"The effects of theobromine, a xanthine derivative, on the testis were compared between rats dosed for 2 and 4 weeks to determine whether a 2-week dosing period is long enough to detect toxicity."( Collaborative work to evaluate toxicity on male reproductive organs by repeated dose studies in rats 22). Effects of 2- and 4-week administration of theobromine on the testis.
Fujioka, M; Funabashi, H; Kohchi, M; Matsuoka, N; Tateishi, Y, 2000
)
0.86
" The variability in CYP1A2 activity in healthy adults, based on data after oral and intravenous dosage (CLm, CL and AUC), ranged from 34 to 42%."( Uncertainty factors for chemical risk assessment. human variability in the pharmacokinetics of CYP1A2 probe substrates.
Dorne, JL; Renwick, AG; Walton, K, 2001
)
0.31
" DMPX (10 microM) caused a leftward shift of the inhibitory dose-response curves for d-tubocurarine (0."( Endogenous adenosine prevents post-tetanic release facilitation mediated by alpha3beta2 nicotinic autoreceptors.
Correia-de-Sá, P; Faria, M; Timóteo, MA, 2003
)
0.32
" For caffeine and scopolamine, even the lowest dosage tested (5 mg/horse/day and 2 mg/horse/day respectively) induced detectable concentrations of the molecule in urine."( Urinary excretion of dietary contaminants in horses.
Bonnaire, Y; Julliand, V; Lallemand, A; Respondek, F, 2006
)
0.33
" The methods used at NIST to determine the concentration levels of caffeine, theobromine, and theophylline in SRM 3243 Ephedra-Containing Solid Oral Dosage Form and SRM 3244 Ephedra-Containing Protein Powder used reversed-phase liquid chromatography with absorbance detection and tandem mass spectrometry."( Determination of caffeine and caffeine-related metabolites in ephedra-containing standard reference materials using liquid chromatography with absorbance detection and tandem mass spectrometry.
Mitvalsky, S; Roman, M; Satterfield, MB; Sharpless, KE; Thomas, JB; Yen, J,
)
0.36
" Longer term dose-response randomized controlled trials are required to determine the sustainability of the short-term effects and the optimal dose."( Flavan-3-ols, theobromine, and the effects of cocoa and chocolate on cardiometabolic risk factors.
Berends, LM; Cassidy, A; van der Velpen, V, 2015
)
0.78
"Accurate quantitative measurement of drugs and their metabolites is important as this can be used to establish long-term abuse of illicit materials as well as establish accurate drug dosing for legal therapeutics."( Simultaneous multiplexed quantification of caffeine and its major metabolites theobromine and paraxanthine using surface-enhanced Raman scattering.
Alharbi, O; Goodacre, R; Xu, Y, 2015
)
0.65
"Model showed fluoride dose-response for both variables (2×F>F>placebo)."( The effects of fluoride, strontium, theobromine and their combinations on caries lesion rehardening and fluoridation.
Lippert, F, 2017
)
0.73
" Dose-response relationship analysis indicated nonlinear correlations between the likelihood of low cognitive performance and die-tary theobromine (total intake and that from chocolate, coffee, and cream)."( Correlation between dietary theobromine intake and low cognitive performance in older adults in the United States: A cross-sectional study based on the National Health and Nutrition Examination Survey.
Han, M; Shen, X; Song, R; Wang, X; Zhan, R; Zhao, L, 2023
)
1.41
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (13 Product(s))

Product Categories

Product CategoryProducts
Other1
Produits de la mer, Poissons et dérivés, Poissons, Poissons gras, Filets de poissons, Harengs, Harengs marinés, Filets de harengs1
Food & Beverages4
Vitamins & Supplements2
Active Lifestyle & Fitness5

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Eco Teas Holy Mate Calm Energy Tea Bags -- 24 Tea BagsEco TeasFood & BeveragesCaffeine, Theobromine2024-11-29 10:47:42
Eco Teas Organic Loose Leaf Tea Yerba Mate -- 1 lbEco TeasFood & BeveragesCaffeine, Theobromine2024-11-29 10:47:42
Eco Teas Organic Yerba Mate Unsmoked -- 24 Tea BagsEco TeasFood & BeveragesCaffeine, Niacin, Theobromine2024-11-29 10:47:42
Eco Teas Organic Yerba Mate Unsmoked Loose Tea -- 1 lbEco TeasFood & BeveragesCaffeine, Theobromine2024-11-29 10:47:42
Irwin Naturals Steel-Libido Pink™ for Women -- 60 Liquid SoftgelsIrwin NaturalsVitamins & Supplementsannatto, leaf, glycerin, Theobromine2024-11-29 10:47:42
Irwin Naturals Steel-Libido RED -- 150 Liquid SoftgelsIrwin NaturalsVitamins & Supplementsannatto, leaf, CoQ10, glycerin, Theobromine2024-11-29 10:47:42
VMI Sports KXR Pre Workout Blue Shark Gummy -- 30 ServingsVMI SportsActive Lifestyle & Fitness Citric acid, Beta-Alanine, Choline, Citric acid, Vitamin B3, Taurine, Theobromine, sucralose, Vitamin B122024-11-29 10:47:42
VMI Sports KXR Pre Workout Gummy Bear -- 30 ServingsVMI SportsActive Lifestyle & Fitness Citric acid, Beta-Alanine, Choline, Citric acid, Vitamin B3, Taurine, Theobromine, sucralose, Vitamin B122024-11-29 10:47:42
VMI Sports KXR Pre Workout Miami Vice -- 30 ServingsVMI SportsActive Lifestyle & Fitness Citric acid, Beta-Alanine, Choline, Citric acid, Vitamin B3, Taurine, Theobromine, sucralose, Vitamin B122024-11-29 10:47:42
VMI Sports KXR Sport Pre-Workout Blue Shark Gummy -- 30 ServingsVMI SportsActive Lifestyle & Fitness Citric acid, Beta-Alanine, Chloride, Citric acid, Niacin, L-Taurine, Theobromine, sucralose, Vitamin B122024-11-29 10:47:42
VMI Sports KXR Sport Pre-Workout Gummy Bear -- 30 ServingsVMI SportsActive Lifestyle & Fitness Citric acid, Beta-Alanine, Chloride, Citric acid, Niacin, L-Taurine, Theobromine, sucralose, Vitamin B122024-11-29 10:47:42

Roles (7)

RoleDescription
vasodilator agentA drug used to cause dilation of the blood vessels.
bronchodilator agentAn agent that causes an increase in the expansion of a bronchus or bronchial tubes.
adenosine receptor antagonistAn antagonist at any adenosine receptor.
food componentA physiological role played by any substance that is distributed in foodstuffs. It includes materials derived from plants or animals, such as vitamins or minerals, as well as environmental contaminants.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
human blood serum metaboliteAny metabolite (endogenous or exogenous) found in human blood serum samples.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
dimethylxanthine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (7)

PathwayProteinsCompounds
Caffeine Metabolism821
theobromine biosynthesis I09
caffeine biosynthesis I011
theobromine biosynthesis II (via xanthine)06
caffeine biosynthesis I012
caffeine degradation IV (bacteria, via demethylation and oxidation)016
caffeine degradation III (bacteria, via demethylation)521
Caffeine and theobromine metabolism011

Protein Targets (37)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Fumarate hydrataseHomo sapiens (human)Potency33.17340.00308.794948.0869AID1347053
USP1 protein, partialHomo sapiens (human)Potency35.48130.031637.5844354.8130AID504865
GLS proteinHomo sapiens (human)Potency35.48130.35487.935539.8107AID624146
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency27.16770.001022.650876.6163AID1224838
EWS/FLI fusion proteinHomo sapiens (human)Potency25.90710.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
retinoid X nuclear receptor alphaHomo sapiens (human)Potency25.11890.000817.505159.3239AID588544
polyproteinZika virusPotency33.17340.00308.794948.0869AID1347053
arylsulfatase AHomo sapiens (human)Potency0.08491.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency13.40770.035520.977089.1251AID504332
peripheral myelin protein 22 isoform 1Homo sapiens (human)Potency84.921423.934123.934123.9341AID1967
chromobox protein homolog 1Homo sapiens (human)Potency39.81070.006026.168889.1251AID488953
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency25.11890.01789.637444.6684AID588834
mitogen-activated protein kinase 1Homo sapiens (human)Potency0.00400.039816.784239.8107AID995
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency24.21320.000627.21521,122.0200AID743219
peptidyl-prolyl cis-trans isomerase NIMA-interacting 1Homo sapiens (human)Potency37.93300.425612.059128.1838AID504536
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency25.11890.031610.279239.8107AID884; AID885
muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)Potency0.01120.00106.000935.4813AID943
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency25.11891.000012.224831.6228AID885
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency26.85450.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Adenosine receptor A1Rattus norvegicus (Norway rat)Ki105.00000.00011.20929.9700AID31860
Adenosine receptor A2bRattus norvegicus (Norway rat)Ki250.00000.00061.353610.0000AID33434; AID33897
Adenosine receptor A2aRattus norvegicus (Norway rat)Ki250.00000.00021.494010.0000AID33434; AID33897
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Molecular Functions (1)

Processvia Protein(s)Taxonomy
G protein-coupled adenosine receptor activityAdenosine receptor A2aRattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
Golgi membraneAdenosine receptor A2aRattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (73)

Assay IDTitleYearJournalArticle
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID33897Antagonism of N-ethylcarboxamido adenosine-stimulated adenylate cyclase associated with stimulation of Adenosine A2 receptor of rat PC12 membranes1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Imidazodiazepinediones: a new class of adenosine receptor antagonists.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID55471Binding affinity to DNA intercalator Acridine orange.2001Journal of medicinal chemistry, Dec-20, Volume: 44, Issue:26
Structural basis for the binding affinity of xanthines with the DNA intercalator acridine orange.
AID30806Binding affinity at Adenosine A2 receptor in rat striatal membrane using [3H]- 5'-N-ethylcarboxamidoadenosine (NECA) at 250 uM1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
Synthesis of paraxanthine analogs (1,7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: structure-activity relationships at adenosine receptors.
AID453747Inhibition of Escherichia coli recombinant N-terminal hexahistidine-tagged CTP synthetase expressed in Escherichia coli BL21 (DE3) assessed as inhibition of CTP formation by continuous spectrophotometric assay in presence of 10 mM L-glutamine and 0.15 mM 2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Inhibition of CTP synthase from Escherichia coli by xanthines and uric acids.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID453744Inhibition of Escherichia coli recombinant N-terminal hexahistidine-tagged CTP synthetase expressed in Escherichia coli BL21 (DE3) assessed as inhibition of CTP formation by continuous spectrophotometric assay in presence of 150 mM NH4Cl2010Bioorganic & medicinal chemistry letters, Jan-01, Volume: 20, Issue:1
Inhibition of CTP synthase from Escherichia coli by xanthines and uric acids.
AID31881Binding affinity at Adenosine A1 receptor in rat brain cortical membrane using [3H]N6-R-phenylisopropyladenosine (R-PIA) as radioligand1993Journal of medicinal chemistry, Oct-29, Volume: 36, Issue:22
Synthesis of paraxanthine analogs (1,7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: structure-activity relationships at adenosine receptors.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID1768730Relative lipophilicity of the compound in methanol assessed as retardation factor by reversed-phase TLC analysis2021Bioorganic & medicinal chemistry letters, 10-01, Volume: 49Estimation of the lipophilicity of purine-2,6-dione-based TRPA1 antagonists and PDE4/7 inhibitors with analgesic activity.
AID33434Binding affinity for Adenosine A2 receptor from rat striatum using [3H]NECA as radioligand1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Imidazodiazepinediones: a new class of adenosine receptor antagonists.
AID511376Neurotoxicity in ddY mouse assessed as changes in behavioral activity at 110 nmol/mouse, icv measured for 60 mins2010Journal of medicinal chemistry, Aug-26, Volume: 53, Issue:16
Novel N-methylated 8-oxoisoguanines from Pacific sponges with diverse neuroactivities.
AID21086Lipid solubility measured as chloroform-water partition coefficient1985Journal of medicinal chemistry, Jan, Volume: 28, Issue:1
1H-2-Benzopyran-1-one derivatives, microbial products with pharmacological activity. Conversion into orally active derivatives with antiinflammatory and antiulcer activities.
AID31860Binding affinity for Adenosine A1 receptor from rat brain using [3H]-PIA as radioligand1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Imidazodiazepinediones: a new class of adenosine receptor antagonists.
AID33411Inhibition of [3H]NECA binding to Adenosine A2 receptor in rat striatal membrane1990Journal of medicinal chemistry, Oct, Volume: 33, Issue:10
Imidazodiazepinediones: a new class of adenosine receptor antagonists.
AID1768729Lipophilicity, logP of compound by shake flask method2021Bioorganic & medicinal chemistry letters, 10-01, Volume: 49Estimation of the lipophilicity of purine-2,6-dione-based TRPA1 antagonists and PDE4/7 inhibitors with analgesic activity.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (1,745)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901015 (58.17)18.7374
1990's236 (13.52)18.2507
2000's205 (11.75)29.6817
2010's201 (11.52)24.3611
2020's88 (5.04)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 83.21

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index83.21 (24.57)
Research Supply Index7.62 (2.92)
Research Growth Index4.46 (4.65)
Search Engine Demand Index152.62 (26.88)
Search Engine Supply Index2.01 (0.95)

This Compound (83.21)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials174 (9.33%)5.53%
Reviews73 (3.92%)6.00%
Case Studies48 (2.58%)4.05%
Observational0 (0.00%)0.25%
Other1,569 (84.17%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (13)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Effectiveness Evaluation of the Theobromine Containing Toothpastes in Controlling Dental Plaque in Children Aged 6-9years(Randomized Controlled Clinical Trial) [NCT05187507]80 participants (Actual)Interventional2021-09-25Completed
Effects of a Cocoa Shot on the Human Brain 2 [NCT02080845]24 participants (Actual)Interventional2014-03-31Completed
Temporal Change of Mood and Cognition in Healthy Subjects After Consumption of Theobromine and/ or Caffeine [NCT01288547]24 participants (Actual)Interventional2008-05-31Completed
The Effects of a Diet Rich in Fat or Theobromine on Intestinal apoA-I mRNA and Protein Expression [NCT02085109]10 participants (Actual)Interventional2014-02-28Completed
The Effects of Short-term Theobromine Supplementation on Vascular Function and Intestinal apoA-I Production in Fasting and in the Postprandial State [NCT02209025]48 participants (Actual)Interventional2014-06-30Completed
"Therapeutic Confirmatory Clinical Trial to Evaluate the Safety and Efficacy of Theobromine Capsule 300mg as an Antitussive Agent in Acute Cough Patients." [NCT01416480]Phase 3332 participants (Actual)Interventional2010-05-31Completed
Consumption of Chocolate in Pregnant Women at High Risk for Preeclampsia. [NCT01431443]Phase 2160 participants (Actual)Interventional2011-05-31Completed
The Effect of Theobromine on Blood Lipid Parameters in Healthy Subjects [NCT01481389]152 participants (Actual)Interventional2010-12-31Completed
The Acute Effect of 2 Different Serving Regimens of Theobromine on Theobromine Concentration in the Blood & Physiological Effects [NCT01544829]12 participants (Actual)Interventional2012-02-29Completed
Food Matrix Effect on Flavanol Absorption, Metabolism and Excretion: Methylxanthines [NCT03526107]10 participants (Actual)Interventional2017-02-16Completed
A Multicentre, Double-Blind, Placebo-Controlled, Adaptive Pivotal Study of the Efficacy and Safety of Oral BC1036 in the Management of Cough [NCT01656668]Phase 3288 participants (Anticipated)Interventional2012-07-31Completed
Effects of a Cocoa Shot on the Human Brain [NCT01924481]6 participants (Actual)Interventional2013-09-30Completed
The Effect of Using Two Desensitizing Agents Alone and In Combination on Dentin Permeability and Hypersensitivity [NCT04340869]30 participants (Anticipated)Interventional2019-08-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]